PCDHGA3, or Protocadherin Gamma A3, is part of the protocadherin family, which plays a critical role in mediating cell-cell adhesion in the nervous system, thereby contributing to the complexity and specificity of neuronal connections. These proteins are essential for the proper functioning of neural circuits, and PCDHGA3, in particular, is involved in the development and maintenance of specific synaptic connections. By promoting homophilic interactions (where cells with the same protocadherins on their surface bind to each other), PCDHGA3 facilitates the sorting and grouping of neurons, which is crucial for the formation of a coherent and functional neural network. This activity supports not only neural development but also plasticity, which is the brain's ability to adapt to new information or injuries.
The inhibition of PCDHGA3 can disrupt normal neuronal development and synaptic function, leading to potential alterations in neural circuitry. One major mechanism of PCDHGA3 inhibition involves the genetic silencing of the PCDHGA3 gene, which can be achieved through epigenetic modifications such as DNA methylation or histone deacetylation. These modifications can prevent the transcription of PCDHGA3, reducing its protein levels and therefore its function in neuronal cell adhesion. Additionally, the stability and surface expression of PCDHGA3 can be modulated by post-translational modifications, including phosphorylation and ubiquitination. These modifications can target PCDHGA3 for degradation or alter its ability to mediate cell adhesion, effectively inhibiting its biological function. Moreover, the inhibition can also occur through the interference of PCDHGA3's homophilic binding capabilities, possibly by the competitive binding of soluble extracellular domains of PCDHGA3 or related molecules, which would prevent the protein from forming functional adhesion complexes on the cell surface. These mechanisms collectively ensure precise control over PCDHGA3 activity, which is essential for the proper development and function of the nervous system.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wnt-C59 | 1243243-89-1 | sc-475634 sc-475634A sc-475634B | 5 mg 10 mg 50 mg | $214.00 $326.00 $1275.00 | 1 | |
Inhibits the Wnt signaling pathway, which can have a downstream effect on PCDHGA3-mediated adhesion processes. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
A Rho-associated kinase inhibitor that can alter cytoskeletal arrangements, subsequently affecting PCDHGA3-based adhesion. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
PI3K inhibitor, which impacts Akt signaling, thus having a downstream effect on cellular processes involving PCDHGA3. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
JNK inhibitor that can disrupt MAPK signaling, impacting cellular processes in which PCDHGA3 is involved. | ||||||
DAPT | 208255-80-5 | sc-201315 sc-201315A sc-201315B sc-201315C | 5 mg 25 mg 100 mg 1 g | $40.00 $120.00 $480.00 $2141.00 | 47 | |
By inhibiting γ-secretase, DAPT interferes with Notch signaling, which could subsequently impact PCDHGA3-mediated cellular activities. | ||||||
XAV939 | 284028-89-3 | sc-296704 sc-296704A sc-296704B | 1 mg 5 mg 50 mg | $36.00 $117.00 $525.00 | 26 | |
A tankyrase inhibitor that can inhibit Wnt/β-catenin signaling, thus having a downstream effect on PCDHGA3. | ||||||
ZM-447439 | 331771-20-1 | sc-200696 sc-200696A | 1 mg 10 mg | $153.00 $356.00 | 15 | |
Inhibits Aurora kinase A and B, which may alter cell cycle-dependent phosphorylation states that could be necessary for PCDHGA3 function. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
Src-family kinase inhibitor that can influence focal adhesion and thereby modify PCDHGA3 function. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
By inhibiting MEK1, PD98059 can affect ERK signaling, indirectly modifying PCDHGA3-mediated processes. | ||||||